1. Home
  2. WNEB vs MDWD Comparison

WNEB vs MDWD Comparison

Compare WNEB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WNEB
  • MDWD
  • Stock Information
  • Founded
  • WNEB 1853
  • MDWD 2000
  • Country
  • WNEB United States
  • MDWD Israel
  • Employees
  • WNEB N/A
  • MDWD N/A
  • Industry
  • WNEB Savings Institutions
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • WNEB Finance
  • MDWD Health Care
  • Exchange
  • WNEB Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • WNEB 165.5M
  • MDWD 179.1M
  • IPO Year
  • WNEB N/A
  • MDWD 2014
  • Fundamental
  • Price
  • WNEB $8.65
  • MDWD $16.57
  • Analyst Decision
  • WNEB Hold
  • MDWD Strong Buy
  • Analyst Count
  • WNEB 4
  • MDWD 1
  • Target Price
  • WNEB $8.50
  • MDWD $28.00
  • AVG Volume (30 Days)
  • WNEB 33.0K
  • MDWD 64.7K
  • Earning Date
  • WNEB 10-22-2024
  • MDWD 08-14-2024
  • Dividend Yield
  • WNEB 3.21%
  • MDWD N/A
  • EPS Growth
  • WNEB N/A
  • MDWD N/A
  • EPS
  • WNEB 0.63
  • MDWD N/A
  • Revenue
  • WNEB $74,435,000.00
  • MDWD $20,141,000.00
  • Revenue This Year
  • WNEB N/A
  • MDWD $30.16
  • Revenue Next Year
  • WNEB $5.16
  • MDWD $18.44
  • P/E Ratio
  • WNEB $13.74
  • MDWD N/A
  • Revenue Growth
  • WNEB N/A
  • MDWD N/A
  • 52 Week Low
  • WNEB $6.00
  • MDWD $7.26
  • 52 Week High
  • WNEB $9.25
  • MDWD $24.00
  • Technical
  • Relative Strength Index (RSI)
  • WNEB 61.40
  • MDWD 41.90
  • Support Level
  • WNEB $8.58
  • MDWD $16.25
  • Resistance Level
  • WNEB $8.99
  • MDWD $17.48
  • Average True Range (ATR)
  • WNEB 0.18
  • MDWD 0.97
  • MACD
  • WNEB -0.04
  • MDWD -0.23
  • Stochastic Oscillator
  • WNEB 48.33
  • MDWD 13.02

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: